FDA Approves Osimertinib + Chemotherapy for EGFR-mutated Non-small Cell Lung Cancer

On February 16, the US Food and Drug Administration (FDA) approved osimertinib in combination with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

For more information read the FDA announcement and the AstraZeneca Pharmaceuticals announcement. 

Posted 2/19/2024